Skip to main content
TipRanks
Go Ultimate75% OFF

Allogene Therapeutics (ALLO) Stock Statistics & Valuation Metrics

1,854 Followers

Total Valuation

Allogene Therapeutics has a market cap or net worth of $290.58M. The enterprise value is $337.73M.

Market Cap
$290.58M
Enterprise Value
$337.73M

Share Statistics

Allogene Therapeutics has 346,467,320 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
346,467,320
Owned by Insiders
6.58%
Owned by Institutions
55.32%

Financial Efficiency

Allogene Therapeutics’s return on equity (ROE) is -0.65 and return on invested capital (ROIC) is -52.84%.

Return on Equity (ROE)
-0.65
Return on Assets (ROA)
-0.46
Return on Invested Capital (ROIC)
-52.84%
Return on Capital Employed (ROCE)
-0.54
Revenue Per Employee
0
Profits Per Employee
-1.26M
Employee Count
151
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Allogene Therapeutics is -1.33. Allogene Therapeutics’s PEG ratio is -0.03.

PE Ratio
-1.33
PS Ratio
62.63
PB Ratio
0.74
Price to FCF
-2.67
Price to Operating Cash Flow
-2.67
PEG Ratio
-0.03

Income Statement

In the last 12 months, Allogene Therapeutics had revenue of 0 and earned -190.89M in profits. Earnings per share was -0.87.

Revenue
0
Gross Profit
-12.36M
Operating Income
-206.93M
Pretax Income
-190.89M
Net Income
-190.89M
EBITDA
-177.45M
Earnings Per Share (EPS)
-0.87

Cash Flow

In the last 12 months, operating cash flow was -108.63M and capital expenditures -184,000, giving a free cash flow of -108.81M billion.

Operating Cash Flow
-108.63M
Free Cash Flow
-108.81M
Free Cash Flow per Share
-0.31

Dividends & Yields

Allogene Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-37.45%
Earnings Yield
-60.10%

Stock Price Statistics

Beta
1.51
52-Week Price Change
-30.17%
50-Day Moving Average
1.41
200-Day Moving Average
1.96
Relative Strength Index (RSI)
23.39
Average Volume (3m)
7.40M

Important Dates

Allogene Therapeutics upcoming earnings date is Mar 18, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 05, 2026
Next Earnings Date
Mar 18, 2027
Ex-Dividend Date
―

Financial Position

Allogene Therapeutics as a current ratio of 7.93, with Debt / Equity ratio of 28.46%

Current Ratio
7.93
Quick Ratio
7.93
Debt to Market Cap
0.00
Net Debt to EBITDA
-0.18
Interest Coverage Ratio
-192.50

Taxes

In the past 12 months, Allogene Therapeutics has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Allogene Therapeutics EV to EBITDA ratio is -2.03, with an EV/FCF ratio of -3.03.

EV to Sales
70.98
EV to EBITDA
-2.03
EV to Free Cash Flow
-3.03
EV to Operating Cash Flow
-3.03

Balance Sheet

Allogene Therapeutics has $292.96M in cash and marketable securities with $68.04M in debt, giving a net cash position of $224.92M billion.

Cash & Marketable Securities
$292.96M
Total Debt
$68.04M
Net Cash
$224.92M
Net Cash Per Share
$0.65
Tangible Book Value Per Share
$1.13

Margins

Gross margin is 100.00%, with operating margin of -4099.33%, and net profit margin of -3759.98%.

Gross Margin
100.00%
Operating Margin
-4099.33%
Pretax Margin
-3759.98%
Net Profit Margin
-3759.98%
EBITDA Margin
-3490.75%
EBIT Margin
-3731.21%

Analyst Forecast

The average price target for Allogene Therapeutics is $9.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
$9.25
Price Target Upside
1003.82% Upside
Analyst Consensus
Strong Buy
Analyst Count
5
Revenue Growth Forecast
―
EPS Growth Forecast
36.37%

Scores

Smart Score
7
AI Score
46